Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

5.155 +0.215 (+4.35%)
Streaming Delayed Price Updated: 12:34 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Top 3 Health Care Stocks That Could Blast Off This Month
Via Benzinga
3 Small-Cap Stocks That Are Ready to Rocket Higher
With lower interest rates and lower corporate taxes more likely, it's a good time to consider three small-cap stocks that present a buying opportunity 
Via MarketBeat
Topics Government
Exposures Political
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
Rocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, and improved heart health. 
Via Benzinga
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Via Benzinga
RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024
RCKT stock results show that Rocket Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Analyst Ratings for Rocket Pharmaceuticals
Via Benzinga
Analyst Expectations for Rocket Pharmaceuticals's Future
Via Benzinga
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I. The FDA requested additional CMC... 
Via Benzinga
Exposures Product Safety
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist. 
Via Talk Markets
RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024
RCKT stock results show that Rocket Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
7 Speculative Stocks to Double Your Money THIS Year
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around. 
Via InvestorPlace
Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning, with the Dow Jones futures falling more than 40 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Rocket Pharmaceuticals Stock Sees Improved Price Strength
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 
Via Investor's Business Daily
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
Rocket could launch its medicines sooner, but Intellia is aiming for larger markets. 
Via The Motley Fool
Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully
Its near-term risks are subtle but bigger than their flying stock price might indicate. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, under followed and emerging stocks. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. 
Via Benzinga
Dow Turns Lower; KULR Technology Group Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Dow Jones falling 100 points on Wednesday. The Dow traded down 0.29% to 34,545.66 while the NASDAQ rose 0.22% to 13,803.43. The S&P 500,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?
With Rocket Pharmaceuticals reaching a Phase II agreement with the FDA, RCKT stock soared, though some concerns linger. 
Via InvestorPlace
Exposures Product Safety
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Gains 50 Points; US Crude Oil Inventories Rise
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 50 points on Wednesday. The Dow traded up 0.16% to 34,701.06 while the NASDAQ rose 0.44% to 13,834.85. The S&P 500,... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy. 
Via The Motley Fool
What's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today?
On Tuesday, Rocket Pharmaceuticals Inc (NASDAQ: RCKT) announced that alignment has been reached with the FDA on the global Phase 2 pivotal trial of RP-A501  
Via Benzinga
Exposures Product Safety
Moderna, REV Group, Rocket Pharmaceuticals And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in... 
Via Benzinga
Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.